glp/gip/glucagon & cagrilintide The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor The next frontier in metabolic

Notably, SGLT2 inhibitors enhance autophagy by improving mitochondrial function, and their combined use with WNT inhibitors synergistically suppresses inflammatory cascades through autophagy-dependent mitochondrial quality control, establishing a dual protective mechanism of metabolic regulation-immune remodeling (160, 161)

This means the pituitary still regulates how much GH it releases, reducing the risk of the kind of above normal hormone levels that can occur with direct HGH injections

It supports healing from ulcers, leaky gut syndrome, IBS, and other inflammatory bowel issues

Often used alongside other peptides in a supervised protocol

Nothing urgent, but enough to make me think harder about what I was doing for my health

Biological Activity Cagrilintide and semaglutide, when co-administered, produce synergistic reductions in bodyweight (up to ~1517% over 2032 weeks in clinical trials) and significant improvements in glycemic parameters, including HbA1c and fasting glucose